English
Побочные эффекты системных препаратов интерферонов
DOI: https://dx.doi.org/10.18565/therapy.2024.9.111-117
Ю.В. Червинец, В.С. Беляев, М.С. Юхимец, А.А. Нассер, А.С. Погосян
ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России
Литература
1. Cao L., Zhang L., Zhang X. et al. Types of interferons and their expression in plant systems. J Interferon Cytokine Res. 2022; 42(2): 62–71. https://doi.org/10.1089/jir.2021.0148. PMID: 35171703. 2. Castro L.S., Lobo G.S., Pereira P. et al. Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation. Vaccines (Basel). 2021; 9(4): 328. https://doi.org/10.3390/vaccines9040328. PMID: 33915863. PMCID: PMC8065594. 3. Forsyth C.J., Chan W.-H., Grigg A.P. et al. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms. Intern Med J. 2019; 49(8): 948–54. https://doi.org/10.1111/imj.14154. PMID: 30411442. 4. Yeh M.-L., Huang J.-F., Dai C.-Y. et al. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. Expert Opin Drug Metab Toxicol. 2019; 15(10): 779–85. https://doi.org/10.1080/17425255.2019.1678584. PMID: 31593639. 5. Bhattacharya D., Aronsohn A., Price J., Lo Re V.; AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2023 update: AASLD-IDSA Recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2023: ciad319. https://doi.org/10.1093/cid/ciad319. PMID: 37229695. 6. Smith J.R., Ariano R.E., Toovey S. The use of antiviral agents for the management of severe influenza. Crit Care Med. 2010; 38(4 Suppl): e43–51. https://doi.org/10.1097/CCM.0b013e3181c85229. PMID: 19935416. 7. Ascierto P.A., Chiarion-Sileni V., Muggiano A. et al. Interferon alpha for the adjuvant treatment of melanoma: Review of international literature and practical recommendations from an expert panel on the use of interferon. J Chemother. 2014; 26(4): 193–201. https://doi.org/10.1179/1973947813y.0000000154. PMID: 24621162. 8. Stickel F., Helbling B., Heim M. et al. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. J Viral Hepat. 2012; 19(2): 77–87. https://doi.org/10.1111/j.1365-2893.2011.01527.x. PMID: 22239497. 9. Ramos M.S., Mardegan M.C., Tirone N.R. The clinical use of type 1 interferon in gynecology. Eur J Gynaecol Oncol. 2010; 31(2): 145–50. PMID: 20527228. 10. Sleijfer S., Bannink M., Van Gool A.R. et al. Side effects of interferon-alpha therapy. Pharm World Sci. 2005; 27(6): 423–31. https://doi.org/10.1007/s11096-005-1319-7. PMID: 16341948. 11. Nachnani J.S., Rao G.A., Bulchandani D. et al. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin. Ann Hematol. 2010; 89(2): 121–25. https://doi.org/10.1007/s00277-009-0774-y. PMID: 19565241. 12. Valentine A.D., Meyers C.A. Neurobehavioral effects of interferon therapy, current psychiatry reports. Curr Psychiatry Rep. 2005; 7(5): 391–95. https://doi.org/10.1007/s11920-005-0042-3. PMID: 16216160. 13. Fragoso Y.D., Paggiaro M.S., Mastromauro R. et al. Literature systematic review on the ophthalmological side effects of interferons. Arq Bras Oftalmol. 2011; 74(4): 306–10. https://doi.org/10.1590/s0004-27492011000400017. PMID: 22068863. 14. (Lapinski T.W., Prokopowicz D. The neuropsychiatric side effects of the interferon therapy in patients with chronic hepatitis B and C. Pol Merkur Lekarski. 1999; 7(37): 8–11 (In Polish)). PMID: 10522402. 15. Huckans M., Fuller B., Wheaton V. et al. A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res. 2015; 78(2): 184–92. https://doi.org/10.1016/j.jpsychores.2014.07.020. PMID: 25219976. PMCID: PMC4435678. 16. Ingimarsson S., Cantell K., Strander H. Side effects of long-term treatment with human leukocyte interferon. J Infect Dis. 1979; 140(4): 560–63. https://doi.org/10.1093/infdis/140.4.560. PMID: 292735. 17. Scott G.M. Interferon: Pharmacokinetics and toxicity. Philos Trans R Soc Lond B Biol Sci. 1982; 299(1094): 91–107. https://doi.org/10.1098/rstb.1982.0109. PMID: 6183699. 18. Wu W., Metcalf J.P. The role of type I ifns in influenza: Antiviral superheroes or immunopathogenic villains? J Innate Immun. 2020; 12(6): 437–47. https://doi.org/10.1159/000508379. PMID: 32564033. PMCID: PMC7747089. 19. Flores-Robles B.J., Sangüesa-Gómez C.P., Mateos C.B. et al. Sarcoidosis developing after treatment with interferon alpha in a patient with hepatitis C: An association every physician should know. Rev Gastroenterol Mex. 2017; 82(2): 185–86. https://doi.org/10.1016/j.rgmx.2016.01.005. PMID: 27161792. 20. Ortiz Salvador J.M., Victoria Martínez A.M., Ferrer D.S. et al. Interferon alfa-induced sarcoidosis resolving without drug withdrawal. JAAD Case Rep. 2016; 2(2): 146–49. https://doi.org/10.1016/j.jdcr.2016.02.003. PMID: 27222872. PMCID: PMC4864091. 21. Chiang C.-H., Lai F.-J. Sarcoidosis on the injection sites following treatment of interferon-alpha and ribavirin for hepatitis C. J Formos Med Assoc. 2014; 113(12): 981–82. https://doi.org/10.1016/j.jfma.2014.07.008. PMID: 25187070. 22. Bush A.E., Hymes S.R., Silapunt S. Lichenoid dermatitis prom interferon alpha-2a in a patient with metastatic renal cell carcinoma and seronegative HCV. J Drugs Dermatol. 2017; 16(7): 714–16. PMID: 28697228. 23. Rahmani H., Davoudi-Monfared E., Nourian A. et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020; 88: 106903. https://doi.org/10.1016/j.intimp.2020.106903. PMID: 32862111. PMCID: PMC7445008. 24. Kavanagh D., McGlasson S., Jury A. et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016; 128(24): 2824–33. https://doi.org/10.1182/blood-2016-05-715987. PMID: 27663672. PMCID: PMC5159705. 25. Reddy K.R. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis. 2004; 24 Suppl 2: 33–38. https://doi.org/10.1055/s-2004-832926. PMID: 15346244. 26. Kang H.Y., Shin M.C. Pegylated interferon-associated severe retinopathy in a patient with chronic hepatitis. Korean J Ophthalmol. 2012; 26(2): 147–50. https://doi.org/10.3341/kjo.2012.26.2.147. PMID: 22511844. PMCID: PMC3325622. 27. Choi J.W., Lee J.S., Paik W.H. et al. Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C. Clin Mol Hepatol. 2016; 22(1): 168–71. https://doi.org/10.3350/cmh.2016.22.1.168. PMID: 27044768. PMCID: PMC4825169. 28. Song J.S., Sohn J.H., Jeong J.Y. et al. Repeated panniculitis induced by pegylated interferon alpha 2a in a patient with chronic hepatitis C. Korean J Gastroenterol. 2016; 67(5): 272–76. https://doi.org/10.4166/kjg.2016.67.5.272. PMID: 27206440. 29. El-Dosouky I.I., Elhawari S., Emara M.H., Hamed E.F. Types and predictors of interferon/ribavirin induced cardiac complications in the Egyptian patients with chronic hepatitis C virus. Zagazig University Medical Journal. 2014; 20(5): 1–11. https://doi.org/10.21608/zumj.2014.4427. 30. Xia C., Vijayan M., Pritzl C.J. et al. Hemagglutinin of influenza A virus antagonizes type I interferon (IFN) responses by inducing degradation of type I IFN receptor 1. J Virol. 2015; 90(5): 2403–17. https://doi.org/10.1128/JVI.02749-15. PMID: 26676772. PMCID: PMC4810695. 31. Xia C., Wolf J.J., Vijayan M. et al. Casein kinase 1α mediates the degradation of receptors for type I and type II interferons caused by hemagglutinin of influenza A virus. J Virol. 2018; 92(7): e00006–18. https://doi.org/10.1128/JVI.00006-18. PMID: 29343571. PMCID: PMC5972889.
Об авторах / Для корреспонденции
Юлия Вячеславовна Червинец, д. м. н., профессор, заведующая кафедрой микробиологии и вирусологии с курсом иммунологии ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России. Адрес: 170100, г. Тверь, ул. Советская, д. 4.
E-mail: julia_chervinec@mail.ru
ORCID: https://orcid.org/0000-0001-9209-7839
Всеволод Станиславович Беляев, ассистент кафедры микробиологии и вирусологии с курсом иммунологии ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России. Адрес: 170100, г. Тверь, ул. Советская, д. 4.
E-mail: seva.belyaev.99@mail.ru
ORCID: https://orcid.org/0000-0002-7165-5077
Мария Сергеевна Юхимец, студентка 3-го курса лечебного факультета ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России. Адрес: 170100, г. Тверь, ул. Советская, д. 4.
E-mail: masha.yuhimec@mail.ru
Анастасия Анисовна Нассер, студентка 3-го курса лечебного факультета ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России. Адрес: 170100, г. Тверь, ул. Советская, д. 4.
E-mail: nastya2002nasser2002@gmail.com
Альберт Самвелович Погосян, студент 5-го курса стоматологического факультета ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России. Адрес: 170100, г. Тверь, ул. Советская, д. 4.
E-mail: albert-pogosyan-2001@mail.ru
Похожие статьи
